Listen free for 30 days

Listen with offer

Get this deal Try for £0.00
Offer ends May 1st, 2024 11:59PM GMT. Terms and conditions apply.
£7.99/month after 3 months. Renews automatically.
Pick 1 audiobook a month from our unmatched collection - including bestsellers and new releases.
Listen all you want to thousands of included audiobooks, Originals, celeb exclusives, and podcasts.
Access exclusive sales and deals.
£7.99/month after 30 days. Renews automatically. See here for eligibility.
Pick 1 audiobook a month from our unmatched collection - including bestsellers and new releases.
Listen all you want to thousands of included audiobooks, Originals, celeb exclusives, and podcasts.
Access exclusive sales and deals.
製薬　大リストラ(週刊東洋経済ｅビジネス新書Ｎo.369) cover art

製薬　大リストラ(週刊東洋経済ｅビジネス新書Ｎo.369)

By: 週刊東洋経済編集部
Narrated by: 海老塚 久蔵
Get this deal Try for £0.00

Pay £99p/month. After 3 months pay £7.99/month. Renews automatically. See terms for eligibility.

£7.99/month after 30 days. Renews automatically. See here for eligibility.

Buy Now for £10.39

Buy Now for £10.39

Pay using card ending in
Switch payment method
By completing your purchase, you agree to Audible's Conditions of Use and authorise Audible to charge your designated card or any other card on file. Please see our Privacy Notice, Cookies Notice and Interest-based Ads Notice.

Summary

本タイトルには付属資料・PDFが用意されています。ご購入後、デスクトップのライブラリー、またはアプリ上の「目次」でご確認ください。（アプリバージョン：Android 2.40以上、iOS 3.11以上）

経営環境が厳しい製薬業界では、薬価の引き下げや後発品の台頭、大型新薬の開発難などがあっても、製薬は研究開発費を確保することが生き残るための必須条件だ。そこで、効率化の白羽の矢が立つのは営業体制だ。コロナ禍で対面営業が激変、「ＭＲ君」などＩＴ化の急拡大で、構造変化の影響を大きく受けるのはＭＲ（医薬情報担当者）だ。だが人員リストラだけで解決できるのか。風雲急を告げているＭＲの将来、製薬会社の苦闘を検証する。

本誌は『週刊東洋経済』２０２０年１２月１９日号掲載の２８ページ分を電子化したものです。情報は底本編集当時のものです。
©東洋経済新報社 (P)2022 Audible, Inc.
Management
Show More Show Less

What listeners say about 製薬　大リストラ(週刊東洋経済ｅビジネス新書Ｎo.369)

Average customer ratings

Reviews - Please select the tabs below to change the source of reviews.

Audible.co.uk reviews

Amazon reviews
No Reviews are Available